Nil Tandogan Gray received her double BSc in Chemical Engineering and Biology from Middle East Technical University in Ankara, Turkiye, and completed her PhD in Chemical Engineering at Northeastern University in Boston in 2016. After graduation, Nil joined Synthetic Molecule Design and Development (SMDD) at Eli Lilly and Company as a process engineer. Within SMDD, her work focused on DS process development of peptide assets, and establishment and execution of new platforms for manufacturing .
In 2021, Nil joined the rotational program within Lilly and completed two one-year rotations within Lilly Research Laboratories. In her first rotation in Molecular Pharmacology at Discovery Chemistry Research & Technologies department, Nil developed and applied chemical proteomics methods while gaining experience in the drug discovery process. Her second rotation in Bioproduct R&D organization allowed her to lead the upstream process development of a monoclonal antibody asset and support the AAV modality.
With her broadened knowledge in drug discovery and development, Nil returned to SMDD in 2024 as a Director of Engineering, where she continues to deliver engineering solutions to synthetic peptide process development.”